Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Mcelroy (Edinburgh (Edinburgh), United Kingdom), J. Davis (Edinburgh (Edinburgh), United Kingdom), A. Marsden (Edinburgh (Edinburgh), United Kingdom), P. Filis (Edinburgh (Edinburgh), United Kingdom), D. Spark (Edinburgh (Edinburgh), United Kingdom), I. Love (Edinburgh (Edinburgh), United Kingdom). Improved assay for the quantification of hydroyproline (collagen) in animal models of Idiopathic Pulmonary Fibrosis.. 729

Member's Comments

No comment yet.

Related content which might interest you: Metabolic shift during TGF- β-induced collagen synthesis Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pulmonary fibroblasts are affected by notch ligands in vitro Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 LATE-BREAKING ABSTRACT: Fibroblast conditioned matrix: A new approach to study extracellular matrix (ECM) effects in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung Year: 2016 AAV-Tgfb1 vs. bleomycin: Analysis of gene expression profiles in two models of pulmonary fibrosis Source: International Congress 2014 – Novel approaches in transcriptomics and epigenomics in inflammatory lung diseases and lung cancer Year: 2014 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 IPFdatabase – A new tool for a correct application of idiopathic pulmonary fibrosis guidelines Source: International Congress 2014 – ILDs 2 Year: 2014 Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 The myofibroblast in pulmonary fibrosis displays distinct functional characteristics, depending on its source of origin Source: International Congress 2014 – ILDs 3 Year: 2014 Lipoxin (LXA4) as a novel therapy for idiopathic pulmonary fibrosis Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases Year: 2014 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Interstitial pulmonary fibrosis model develpment and identification of early biomarkers by MALDI imaging Source: International Congress 2015 – New insights into IIPs Year: 2015 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014